HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

BACKGROUND&AIMS: Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained-virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether ear...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Hepatol
Main Authors: Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S.A., Penaranda, Guillaume, Coquet, Emilie, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., Halfon, Philippe
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081285/
https://ncbi.nlm.nih.gov/pubmed/26907973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.02.022
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍